Stevanato Group (NYSE:STVN) Price Target Cut to $19.00 by Analysts at Morgan Stanley

Stevanato Group (NYSE:STVN) had its target price reduced by investment analysts at Morgan Stanley from $24.00 to $19.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Stevanato Group in a research report on Monday, December 29th. Jefferies Financial Group set a $17.50 price target on shares of Stevanato Group in a research report on Tuesday, February 10th. KeyCorp decreased their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday. Citigroup reduced their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday. Finally, Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Stevanato Group Trading Down 4.8%

Shares of Stevanato Group stock traded down €0.76 on Friday, hitting €15.15. 104,423 shares of the company’s stock traded hands, compared to its average volume of 737,959. The firm’s 50-day moving average price is €17.69 and its two-hundred day moving average price is €21.71. The stock has a market capitalization of $4.59 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 1.44 and a beta of 0.57. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30. Stevanato Group has a one year low of €13.91 and a one year high of €28.00.

Institutional Trading of Stevanato Group

A number of institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its stake in shares of Stevanato Group by 10.8% during the 1st quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock valued at $8,930,000 after buying an additional 42,731 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Stevanato Group by 4.4% during the second quarter. Envestnet Asset Management Inc. now owns 170,002 shares of the company’s stock valued at $4,153,000 after purchasing an additional 7,232 shares in the last quarter. First Horizon Advisors Inc. lifted its position in Stevanato Group by 14.9% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,833 shares of the company’s stock worth $94,000 after buying an additional 497 shares during the last quarter. Marco Investment Management LLC bought a new stake in shares of Stevanato Group in the 2nd quarter worth approximately $228,000. Finally, Zions Bancorporation National Association UT boosted its stake in shares of Stevanato Group by 9.2% in the 2nd quarter. Zions Bancorporation National Association UT now owns 102,357 shares of the company’s stock valued at $2,501,000 after purchasing an additional 8,648 shares in the last quarter.

More Stevanato Group News

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Reported Q4 results beat expectations (EPS ~€0.21 vs. €0.20) with FY25 revenue +7% (9% at constant currency) and record sales from High‑Value Solutions; management set a 2026 revenue target up to €1.308B with HVS expected to reach ~48% of sales — supports the long‑term growth story. Read More.
• Positive Sentiment: Management reiterated that most capex (~90%) is being directed to HVS (High‑Value Solutions) expansion, which should drive future margin mix improvement and supports buy‑and‑hold theses that emphasize recurring pharma demand. Read More.
• Neutral Sentiment: Earnings call and transcripts provide detail on drivers and near‑term execution; the beat was modest and commentary suggests some margin pressure remains, so investors get clarity but no radical upside surprise. Read More. | Read More.
• Negative Sentiment: Several sell‑side desks trimmed price targets (Citigroup cut PT from $32 to $26 but stayed Buy; KeyCorp/KeyBanc cut from $37 to $32 and kept Overweight). Lower PTs reduce near‑term analyst‑driven upside and can pressure the stock after recent gains. Read More. | Read More.
• Negative Sentiment: The shares had rebounded sharply after the Q4 beat (reports of a ~17% surge), so some of today’s weakness looks like profit‑taking and repositioning; volume is well below average, which can amplify moves. Read More.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.